Related Experiment Video
Updated: Oct 11, 2025
10:34
Measurement of Differentially Methylated INS DNA Species in Human Serum Samples as a Biomarker of Islet β Cell Death
Published on: December 21, 2016
6.5K
Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic Cancer
Lee Ying1, Anup Sharma1, Ankit Chhoda2
1From the Department of Surgery.
Pancreas
|December 3, 2021
Summary
This study shows a promising 4-gene DNA methylation panel for early pancreatic cancer detection. The biomarker panel achieved 94% accuracy, indicating its potential for diagnosing pancreatic cancer.
Area of Science:
- Epigenetics
- Molecular Diagnostics
- Oncology
Background:
- DNA methylation alterations are potential biomarkers for early pancreatic cancer (PC) detection.
- Cell-free DNA (cfDNA) analysis offers a non-invasive approach for PC diagnosis.
Purpose of the Study:
- To investigate the diagnostic capacity of a 4-gene methylation biomarker panel (ADAMTS1, BNC1, LRFN5, PXDN) for early pancreatic cancer detection.
- To evaluate the accuracy of this panel using cfDNA in a case-control study.
Main Methods:
- A genome-wide pharmacoepigenetic approach identified candidate genes: ADAMTS1, BNC1, LRFN5, and PXDN.
- Analyzed cfDNA methylation using methylation on beads technology from pancreatic cancer patients (n=22) and controls (n=10).
- Utilized receiver operating characteristic (ROC) analysis to determine the diagnostic accuracy of individual genes and the combined panel.
Main Results:
- The 4-gene methylation panel (ADAMTS1, BNC1, LRFN5, PXDN) achieved an area under the curve (AUC) of 0.94.
- The panel demonstrated high diagnostic accuracy with 100% sensitivity and 90% specificity.
- Individual gene performance varied, with ADAMTS1 showing the highest AUC (0.93).
Conclusions:
- The developed 4-gene methylation biomarker panel shows significant promise for accurate pancreatic cancer detection.
- Further validation in prospective surveillance trials is warranted to confirm its clinical utility.
